SynthesisMolecular psychiatry2021
Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease.
Open access · greenAbstract readMeta-Analysis
In one paragraph
Synthesis in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 67 citations in OpenAlex.
- Cross-cohort genetic risk prediction for Alzheimer's disease: a transfer learning approach using GWAS and deep learning models.BioData mining · 2025Article
- Recommendations for management and future investigation of psychosis in neurodegenerative disease: Findings from the International Psychogeriatric Association (IPA) working group.International psychogeriatrics · 2025Review
- Leveraging multiomic approaches to elucidate mechanisms of heterogeneity in Alzheimer's disease: Neuropsychiatric symptoms, co-pathologies, and sex differences.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Exploring Potential Medications for Alzheimer's Disease with Psychosis by Integrating Drug Target Information into Deep Learning Models: A Data-Driven Approach.International journal of molecular sciences · 2025Article
- A brain DNA co-methylation network analysis of psychosis in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Emerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer's Disease.CNS drugs · 2025Review
- An artificial intelligence-derived metabolic network predicts psychosis in Alzheimer's disease.Brain communications · 2025Article
- The role of the endocannabinoid system in managing neuropsychiatric symptoms in Alzheimer's disease.Frontiers in psychiatry · 2025Review
- From Classical to Alternative Pathways of 2-Arachidonoylglycerol Synthesis: AlterAGs at the Crossroad of Endocannabinoid and Lysophospholipid Signaling.Molecules (Basel, Switzerland) · 2024Review
- Beyond memory impairment: the complex phenotypic landscape of Alzheimer's disease.Trends in molecular medicine · 2024Review
- Psychosis in Alzheimer's disease is associated with specific changes in brain MRI volume, cognition and neuropathology.Neurobiology of aging · 2024Article
- A Genome-Wide Interaction Study of Erythrocyte ω-3 Polyunsaturated Fatty Acid Species and Memory in the Framingham Heart Study Offspring Cohort.The Journal of nutrition · 2024Article
- Unique transcriptional signatures correlate with behavioral and psychological symptom domains in Alzheimer's disease.Translational psychiatry · 2024Article
- Distinguishing features of depression in dementia from primary psychiatric disease.Discover mental health · 2024Review
- Sex differences in the relationship between depression and Alzheimer's disease-mechanisms, genetics, and therapeutic opportunities.Frontiers in aging neuroscience · 2024Review
- Combination of antidepressants and antipsychotics as a novel treatment option for psychosis in Alzheimer's disease.CPT: pharmacometrics & systems pharmacology · 2023Article
- Unveiling the Enigma: Exploring Risk Factors and Mechanisms for Psychotic Symptoms in Alzheimer's Disease through Electronic Medical Records with Deep Learning Models.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Targeting the post-synaptic proteome has therapeutic potential for psychosis in Alzheimer Disease.Communications biology · 2023Article
- A global view of the genetic basis of Alzheimer disease.Nature reviews. Neurology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 20 institutions in 6 countries.
Mary Ann A DeMichele-SweetDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-6582-7813
Lambertus KleiDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
Byron CreeseUniversity of Exeter Medical School, College of Medicine and Health, Exeter, UK.ORCID http://orcid.org/0000-0001-6490-6037
Janet C HarwoodDivision of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.
Elise A WeamerDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
Lora McClainDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
Rebecca SimsDivision of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.ORCID http://orcid.org/0000-0002-3885-1199
Isabel HernandezResearch Center and Memory Clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Sonia Moreno-GrauResearch Center and Memory Clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Lluís TárragaResearch Center and Memory Clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Mercè BoadaResearch Center and Memory Clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2617-3009
Emilio Alarcón-MartínResearch Center and Memory Clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Sergi ValeroResearch Center and Memory Clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
NIA-LOAD Family Based Study Consortium, Alzheimer’s Disease Genetics Consortium (ADGC)
Yushi LiuGlobal Statistical Science, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0003-4185-4187
Basavaraj HooliNeurodegeneration Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-5461-1507
Dag AarslandDepartment of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London and Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.
Geir SelbaekNorwegian National Advisory Unit in Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.ORCID http://orcid.org/0000-0001-6511-8219
Sverre BerghResearch Centre of Age-related Functional Decline and Disease, Innlandet Hospital Trust, Pb 68, Ottestad, Norway.ORCID http://orcid.org/0000-0001-9593-2967
Arvid RongveDepartment of Research and Innovation, Helse Fonna, Haugesund and Department of Clinical Medicine (K1), University of Bergen, Bergen, Norway.ORCID http://orcid.org/0000-0002-0476-4134
Ingvild SaltvedtGeriatric Department, St. Olav Hospital, University Hospital of Trondheim, Trondheim, Norway.ORCID http://orcid.org/0000-0002-7897-9808
Håvard K SkjellegrindHUNT Research Centre, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Levanger, Norway.ORCID http://orcid.org/0000-0003-3067-0016
Bo EngdahlNorwegian Institute of Public Health, Oslo, Norway.ORCID http://orcid.org/0000-0002-9166-5782
Eystein StordalDepartment of Mental Health, Norwegian University of Science and Technology, Trondheim, Norway.ORCID http://orcid.org/0000-0002-2443-7923
Ole A AndreassenNORMENT Centre, Institute of Clinical Medicine, University of Oslo, and Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-4461-3568
Srdjan DjurovicDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-8140-8061
Lavinia AthanasiuNORMENT, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0002-3321-6997
Davide SeripaDepartment of Hematology and Stem Cell Transplant, Vito Fazzi Hospital, Lecce, Italy.
Barbara BorroniCentre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.ORCID http://orcid.org/0000-0001-9340-9814
Diego AlbaniNeuroscience Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0002-7050-6723
Gianluigi ForloniNeuroscience Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Patrizia MecocciInstitute of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Alessandro SerrettiDepartment of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy.ORCID http://orcid.org/0000-0003-4363-3759
Diana De RonchiDepartment of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy.
Antonis Politis1st Department of Psychiatry, Eginition Hospital, Medical School, National & Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0003-0261-7517
Julie WilliamsDivision of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.ORCID http://orcid.org/0000-0002-4069-0259
Richard MayeuxDepartments of Neurology, Psychiatry and Epidemiology, Columbia University, New York, NY, USA.
Tatiana ForoudMedical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-5549-2212
Agustin RuizResearch Center and Memory Clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2633-2495
Clive BallardUniversity of Exeter Medical School, Exeter, UK.ORCID http://orcid.org/0000-0003-0022-5632
Peter HolmansMRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.ORCID http://orcid.org/0000-0003-0870-9412
Oscar L LopezDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-8546-8256
M Ilyas KambohDepartment of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA.
Bernie DevlinDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0003-2524-4290
Robert A SweetDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA. sweetra@upmc.edu.ORCID http://orcid.org/0000-0001-9154-9709
University of Pittsburgh · USInstituto de Salud Carlos III · ESCardiff University · GBNorwegian University of Science and Technology · NOOslo University Hospital · NOEli Lilly (United States) · USMario Negri Institute for Pharmacological Research · ITUniversity of Bologna · ITUniversity of Exeter · GBColumbia University · USFundació ACE · ESIndiana University School of MedicineInnlandet Hospital Trust · NONational and Kapodistrian University of Athens · GRNorwegian Institute of Public Health · NOOspedale Vito Fazzi · ITStavanger University Hospital · NOUK Dementia Research Institute · GBUniversity of Bergen · NOUniversity of Brescia · IT
Funding
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8MAlzheimer's Disease Genetics ConsortiumU01AG032984 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SCHELLENBERG, GERARD DAVID · 2009 to 2024
$60.4MThe National Institute on Aging (NIA) Late Onset of Alzheimer's Disease (LOAD) Family-Based Study (FBS)U24AG056270 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Gary Wayne Beecham, TATIANA M. FOROUD · 2017 to 2026
$31.4MResearch Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Andrew Franklin Teich · 2020 to 2026
$30.1MResearch Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOWARD J AIZENSTEIN · 2020 to 2026
$29.4MPrediction of Psychosis in Alzheimer DiseaseR01AG027224 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SWEET, ROBERT A · 2007 to 2021
$10.8MGenetic Architecture of Alzheimer’s disease ProteinopathiesR01AG064877 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CRUCHAGA, CARLOS, KAMBOH, M. ILYAS · 2021 to 2024
$8.4MSearch for the Alzheimers GenesR01AG030653 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAMBOH, M. ILYAS · 2009 to 2019
$7.7MSynaptic Resilience to Psychosis in Alzheimer DiseaseR01MH116046 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Julia K Kofler, ROBERT A SWEET · 2018 to 2026
$6.6MGenetics Association in Schizophrenia and Other DisordersR37MH057881 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DEVLIN, BERNIE · 2013 to 2022
$5.4MGENETIC ASSOCIATION IN SCHIZOPHRENIA AND OTHER DISORDERSR01MH057881 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DEVLIN, BERNIE · 1998 to 2012
$4.8MGenetic basis of neuropsychiatric symptoms in Alzheimer's diseaseU01AG079850 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Gary Wayne Beecham, Edward D Huey · 2023 to 2026
$3.0MMedical Research Council G0300429Medical Research Council G0902227Medical Research Council MC_PC_17112Medical Research Council MR/K013041/1Medical Research Council MR/L501517/1NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066468NIA NIH HHS R01 AG027224NIA NIH HHS R01 AG030653NIA NIH HHS R01 AG041718NIA NIH HHS R01 AG062268NIA NIH HHS R01 AG064877NIA NIH HHS R01 AG067015NIA NIH HHS U01 AG032984NIA NIH HHS U01 AG079850NIA NIH HHS U24 AG021886NIA NIH HHS U24 AG056270NIMH NIH HHS R01 MH057881NIMH NIH HHS R01 MH116046NIMH NIH HHS R01 MH120794NIMH NIH HHS R37 MH057881
Abstract
Psychotic symptoms, defined as the occurrence of delusions or hallucinations, are frequent in Alzheimer disease (AD with psychosis, AD + P). AD + P affects ~50% of individuals with AD, identifies a subgroup with poor outcomes, and is associated with a greater degree of cognitive impairment and depressive symptoms, compared to subjects without psychosis (AD - P). Although the estimated heritability of AD + P is 61%, genetic sources of risk are unknown. We report a genome-wide meta-analysis of 12,317 AD subjects, 5445 AD + P. Results showed common genetic variation accounted for a significant portion of heritability. Two loci, one in ENPP6 (rs9994623, O.R. (95%CI) 1.16 (1.10, 1.22), p = 1.26 × 10
Indexed as
Alzheimer DiseasePsychotic DisordersSchizophreniaGenetic Predisposition to DiseaseGenome-Wide Association StudyHallucinationsHumansOxidoreductases Acting on Sulfur Group DonorsPolymorphism, Single NucleotideOxidoreductases Acting on Sulfur Group DonorsSUMF1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.